Prostate Cancer

Enzalutamide in prostate cancer: Hints of added benefit

Enzalutamide (trade name: Xtandi) has been approved since June 2013 for men with metastatic prostate cancer in whom the commonly used hormone blockade is no longer effective and who have already been treated with the cytostatic ...

Dec 06, 2013
popularity not rated yet | comments 0

World first trial to improve prostate cancer care

Researchers and clinicians from the University of Sydney and the Northern Sydney Cancer Centre are leading a world first clinical trial using a tracking system to improve prostate cancer radiotherapy treatment.

Nov 28, 2013
popularity not rated yet | comments 0

Bayer bids 1.8 bn euro for Norway's Algeta

German pharmaceutical group Bayer has made a bid for its Norwegian partner and competitor Algeta, specialised in cancer treatments, for 1.8 billion euro ($2.4 billion), the Nordic company said Tuesday.

Nov 26, 2013
popularity not rated yet | comments 0

Latest Spotlight News

$1,000 pill now hepatitis C treatment of choice

(AP)—A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.

Facial features are the key to first impressions

A new study by researchers in the Department of Psychology at the University of York shows that it is possible to accurately predict first impressions using measurements of physical features in everyday images of faces, such ...

Gender disparities in cognition will not diminish

The study, published in the Proceedings of the National Academy of Science, investigated the extent to which improvements in living conditions and educational opportunities over a person's life affect cognitive abilities and th ...